Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
This table compares the primary peptides studied in rosacea and inflammatory dermatoses based on mechanism, clinical evidence quality, typical concentration ranges, and practical considerations for formulation stability. KPV (Lys…
BPC-157 VEGF modulation, NF- B inhibition, stellate cell suppression 200–500 mcg SQ daily (human equivalent from animal models) Preclinical only. No Phase III human trials Strongest evidence for fibrosis reduction in CCl4 and alc…
Cerebrolysin BDNF pathway activation, neurotrophic factor delivery Meta-analysis: 15–20% cognitive improvement vs placebo (n=839, moderate-severe TBI) 30–50ml daily × 10–21 days IV infusion Requires clinical administration; no at…
Opioid Analgesics CNS pain receptor blockade 30–90 minutes None. Symptom suppression only Effective for acute pain; risk of tolerance and dependence with chronic use Gabapentin/Pregabalin Voltage-gated calcium channel inhibition …
Thymalin Thymic immunomodulation. Reduces IL-6, TNF-alpha, cortisol Peripheral cytokine suppression → reduced microglial activation 6–8 weeks (two cycles) 1–2mg subcutaneous, 5 consecutive days, 25-day rest Best for immune-driven…
TB-500 (Thymosin Beta-4) Modulates T-cell differentiation; increases Treg populations in synovial fluid 34% increase in synovial Treg cells; 47% reduction in inflammation scores (Arthritis Research & Therapy, 2023) 5mg subcutaneo…
Before selecting a peptide protocol, understanding how each candidate differs in mechanism, administration, and evidence level prevents mismatched expectations. BPC-157 Nitric oxide modulation, VEGF upregulation, mucosal repair S…
Cerebrolysin Multi-target neurotrophic activation (BDNF, GDNF, NGF) via Trk receptors Moderate (requires IV administration for CNS effect) Restored dendritic spine density to 87% of wild-type in Shank3-deficient mice; normalized …
Tirzepatide Dual GLP-1/GIP agonist. Reduces insulin, slows gastric emptying Strong (Phase 3 RCT, n=412) Insulin-resistant, BMI ≥27 5–15mg weekly SC GI side effects during titration (35% nausea rate) Semaglutide GLP-1 agonist. Imp…
BPC-157 VEGF pathway activation; promotes angiogenesis and fibroblast migration 200–500 mcg/kg daily (animal models); 100–300 mcg daily (human equivalent) Tendons, ligaments, annulus fibrosus of intervertebral discs 28 days at 2–…
This table compares antimicrobial peptides with demonstrated activity against H pylori based on mechanism, delivery method, and research-stage evidence. BPC-157 Membrane disruption + gastric cytoprotection Oral (encapsulated) or …
The table below compares the three most clinically validated peptides for chest wrinkle reduction across mechanism, concentration, timeline, and professional assessment. Copper Peptides (GHK-Cu) Chelates copper ions to activate l…
BPC-157 VEGF modulation, NO signalling, endothelial repair Restored blood flow 85% vs 40% in ischaemia models; promotes functional angiogenesis 200–500 mcg/day (animal models, SC) Strongest evidence for microvascular repair. Addr…
Copper Peptides (GHK-Cu) Cytokine suppression, collagen remodeling IL-1β, TNF-α downregulation 40–52% reduction in inflammatory lesions (12 weeks) All skin types; particularly effective for post-inflammatory hyperpigmentation Bes…
Thymalin Thymic epithelial regeneration, T-regulatory cell production Reduces systemic inflammation (inflammaging), stabilizes atherosclerotic plaques 5–10mg subcutaneous, 2x weekly IL-6 reduction 18–22%, Treg count increase 28–3…
Thymalin Restores thymic immune-endocrine balance; reduces inflammatory cytokines (IL-6, TNF-alpha) that act on hypothalamic thermoregulation Modulates HPA axis via immune regulation; dampens cytokine-driven hypothalamic activati…
P21 BDNF upregulation, neuroprotection Serotonergic neuron resilience, mood stability Preclinical models, limited human data Strong mechanism for luteal-phase mood symptoms; clinical trials needed Cerebrolysin Neurotrophic factor…
Cerebrolysin Neurotrophic peptide blend (BDNF-like, GDNF-like, NGF-like) supporting neuronal survival and synaptic plasticity May preserve residual orexin neurons (5–15% surviving cells) and stabilise hypothalamic circuits under …
BPC-157 Angiogenesis promotion, VEGF activation, mucosal repair 72% ulcer area reduction in 7 days (rat models); complete healing in 68% by day 14 Intraperitoneal, subcutaneous; oral bioavailability uncharacterised Gastric ulcer …
BPC-157 VEGF pathway activation; angiogenesis in peritubular capillaries Ischemia-reperfusion injury models; cisplatin nephrotoxicity studies 200-500 mcg subcutaneously daily in rodent models (human equivalent dose unvalidated) E…